Overview

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Status:
Completed

Trial end date:
2021-04-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death) during the treatment period.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

Enoxaparin